Silverlon for Left Ventricular Assist Device Infection

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Left Ventricular Assist Device InfectionSilverlon - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test a new protocol for managing drivelines, which are tubes that go from an external pump to an internal device. The new protocol includes a silver-based dressing and a new dressing change protocol. The goal is to reduce the risk of dermatitis and allergies.

Eligible Conditions
  • Left Ventricular Assist Device Infection

Treatment Effectiveness

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: 1 year

1 year
Allergies
Comfort
Driveline infection
Speciation

Trial Safety

Trial Design

2 Treatment Groups

ControlD
1 of 2
SilverD
1 of 2

Active Control

Experimental Treatment

20 Total Participants · 2 Treatment Groups

Primary Treatment: Silverlon · No Placebo Group · N/A

SilverD
Device
Experimental Group · 1 Intervention: Silverlon · Intervention Types: Device
ControlD
Device
ActiveComparator Group · 1 Intervention: Control · Intervention Types: Device
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Silverlon
2020
Completed Phase 2
~160

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year

Who is running the clinical trial?

University of California, San FranciscoLead Sponsor
2,280 Previous Clinical Trials
11,577,564 Total Patients Enrolled
International Consortium of Circulatory Assist CliniciansUNKNOWN
Liviu Klein, MDPrincipal InvestigatorUniversity of California, San Francisco
4 Previous Clinical Trials
830 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are over 18 years of age.